NCT03125928
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active central nervous system (CNS )metastases; Subjects with previously treated brain metastases may participate provided they are stable 
https://ClinicalTrials.gov/show/NCT03125928